PO.IM02.04 · 免疫学

IRF8调控T细胞分化及抗肿瘤效应功能

IRF8 regulates T cell differentiation and anti-tumor effector function

海报缩略图:IRF8调控T细胞分化及抗肿瘤效应功能
编号 4242 展板 10 时间 4/21 09:00–12:00 区域 Section 6 主讲 Zainab Tiamiyu, BS
分会场 Adaptive Immunity in Cancer
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Zainab Tiamiyu1, Dakota Poschel2, Aaron Behdadnia1, Kendra Fick1, Patrick Czabala3, Yang Zhao1, Dafeng Yang3, Sergie BOMBIN4, Kebin LIU3

1Biochemistry and Cancer Biology, Augusta University, Augusta, GA,2Medical College of Georgia, Augusta, GA,3Augusta University, Augusta, GA,4Georgia Cancer Center, Augusta, GA

摘要 Abstract

中文摘要
干扰素调节因子8(IRF8)是一种髓系细胞谱系特异性转录因子,在生理条件下也调控B细胞分化。在癌症等病理条件下,IRF8作为髓源性抑制细胞(MDSCs)的负性调控因子调节抗肿瘤免疫。然而,IRF8在肿瘤微环境中调控适应性免疫应答的功能尚未被完全阐明。因此,我们旨在利用全基因组单细胞多组学构建肿瘤微环境中IRF8调控的免疫细胞分化单细胞图谱。无监督聚类结合基于标志物的注释,在肿瘤浸润白细胞中鉴定出12个主要细胞亚群。IRF8缺失导致髓源性抑制细胞(MDSCs)和记忆性T细胞增多,但浆母细胞、树突状细胞和效应T细胞减少。通路富集分析表明,IRF8主要调控浆母细胞中的多条代谢通路。此外,IRF8缺失增强了肿瘤浸润性效应T细胞中的TCR信号、MTOC1信号、IFNgamma信号及T细胞功能障碍,但在记忆性T细胞中并非如此。这种过度激活与效应T细胞中凋亡通路激活的增强相关。我们的研究结果确定,IRF8调控肿瘤微环境中的浆母细胞-效应T细胞轴,IRF8表达缺失导致浆母细胞减少以及效应T细胞的过度激活和功能障碍,从而引起效应T细胞清除和肿瘤免疫逃逸。
查看英文原文 English abstract
Interferon regulatory factor 8 (IRF8) is a myeloid cell lineage-specific transcription factor that also regulate B cell differentiation under physiological conditions. Under pathological conditions such as cancer, IRF8 acts as a negative regulator of myeloid-derived suppressor cells (MDSCs) to regulate anti-tumor immunity. However, the function of IRF8 in regulation of the adaptive immune response in the tumor microenvironment is incompletely understood. We therefore aimed at building a single cell atlas of IRF8-regulated immune cell differentiation in the tumor microenvironment using genome-wide single-cell multiomics. Unsupervised clustering in combination with maker-based annotation identified 12 major cell subpopulations in tumor-infiltrating leukocytes. IRF8 deficiency resulted in increased myeloid-derived suppressor cells (MDSCs) and memory T cells, but decreased plasmablasts, dendritic cells, and effecter T cells. Pathway enrichment analysis indicates that IRF8 primarily regulates multiple metabolic pathways in plasmablasts. In addition, IRF8 deficiency enhances TCR signaling, MTOC1 signaling, IFNgamma signaling, and T cell dysfunction in tumor-infiltrating effector T cells, but not in memory T cells. This hyperactivation is correlated with increased activation of apoptosis pathways in effector T cells. Our findings determine that IRF8 regulates the plasmablasts-effector T cell axis in the tumor microenvironment, and loss of IRF8 expression leads to decreased plasmablasts and hyper activation and dysfunction of effector T cells, resulting in effector T cell elimination and tumor immune escape.
利益披露 Disclosure
Z. Tiamiyu, None.. A. Behdadnia, None.. K. Fick, None.. Y. Zhao, None.. S. Bombin, None.

← 返回 AACR 2026 检索